Abstract：
BACKGROUND: Certolizumab pegol (CZP) is a TNF-ɑ inhibitor used to treat moderate-to-severe plaque psoriasis (PsO) in adult patients, including women of childbearing potential (WOCBP) and patients with psoriatic arthritis (PsA). There are currently limited real-world data on CZP for treatment of PsO.
OBJECTIVE: To examine the use of CZP for treatment of PsO in clinical practice at two dermatology clinics in Canada.
METHODS: We conducted a retrospective chart analysis of 59 patients with moderate-to-severe psoriasis receiving CZP. Clinical efficacy was measured using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA). Drug survival was analyzed using Kaplan-Meier plots.
RESULTS: Of the 59 patients, 36 (61%) were female, of whom 23 (63.9%) were WOCBP. Twenty-three (39.0%) patients received CZP as their first biologic treatment. The main reasons for choosing CZP were its efficacy in both PsO and PsA, and for WOCBP due to little or no cross-placental transfer. Improvement of symptoms was observed after 3 months of treatment and was maintained for the 12-month analysis period. After 12 months of treatment, the patients\' mean PASI score decreased from 13.0 (±5.8) at baseline to 2.3 (±4.3), mean BSA score from 13.1% (±6.7%) to 1.7% (±2.6%), and mean PGA score from 3.0 (±0.6) to 0.8 (±0.6). Overall CZP drug survival rate was 76.3% at 12 months, with no difference between biologic-naive and biologic-experienced patients.
CONCLUSIONS: CZP was effective and well tolerated in this cohort of patients with moderate-to-severe PsO in a real-world setting.
OBJECTIVE: To examine the use of CZP for treatment of PsO in clinical practice at two dermatology clinics in Canada.
METHODS: We conducted a retrospective chart analysis of 59 patients with moderate-to-severe psoriasis receiving CZP. Clinical efficacy was measured using the Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and Physician Global Assessment (PGA). Drug survival was analyzed using Kaplan-Meier plots.
RESULTS: Of the 59 patients, 36 (61%) were female, of whom 23 (63.9%) were WOCBP. Twenty-three (39.0%) patients received CZP as their first biologic treatment. The main reasons for choosing CZP were its efficacy in both PsO and PsA, and for WOCBP due to little or no cross-placental transfer. Improvement of symptoms was observed after 3 months of treatment and was maintained for the 12-month analysis period. After 12 months of treatment, the patients\' mean PASI score decreased from 13.0 (±5.8) at baseline to 2.3 (±4.3), mean BSA score from 13.1% (±6.7%) to 1.7% (±2.6%), and mean PGA score from 3.0 (±0.6) to 0.8 (±0.6). Overall CZP drug survival rate was 76.3% at 12 months, with no difference between biologic-naive and biologic-experienced patients.
CONCLUSIONS: CZP was effective and well tolerated in this cohort of patients with moderate-to-severe PsO in a real-world setting.
摘要：
背景：塞托珠单抗pegol（CZP）是一种用于治疗成年患者中至重度斑块状银屑病（PsO）的TNF-α抑制剂，包括育龄妇女（WOCBP）和银屑病关节炎（PsA）患者。目前关于治疗PsO的CZP的实际数据有限。
目的：在加拿大的两个皮肤科诊所检查CZP在临床实践中用于治疗PsO。
方法：我们对59例接受CZP治疗的中重度银屑病患者进行了回顾性分析。使用银屑病面积和严重程度指数（PASI）测量临床疗效，体表面积(BSA),和医师全球评估（PGA）。使用Kaplan-Meier图分析药物存活。
结果：在59例患者中，36（61%）为女性，其中23人（63.9%）为WOCBP。23例（39.0％）患者接受CZP作为其首次生物治疗。选择CZP的主要原因是其在PsO和PsA中的疗效，和WOCBP由于很少或没有跨胎盘转移。治疗3个月后观察到症状的改善，并维持12个月的分析期。经过12个月的治疗，患者平均PASI评分从基线时的13.0(±5.8)降至2.3(±4.3),平均BSA评分从13.1%(±6.7%)到1.7%(±2.6%)，平均PGA评分从3.0(±0.6)到0.8(±0.6)。CZP药物12个月生存率为76.3%,未接受生物学治疗的患者和有生物学经验的患者之间没有差异。
结论：CZP是有效的，并且在实际情况下，CZP在中重度PsO患者队列中具有良好的耐受性。
目的：在加拿大的两个皮肤科诊所检查CZP在临床实践中用于治疗PsO。
方法：我们对59例接受CZP治疗的中重度银屑病患者进行了回顾性分析。使用银屑病面积和严重程度指数（PASI）测量临床疗效，体表面积(BSA),和医师全球评估（PGA）。使用Kaplan-Meier图分析药物存活。
结果：在59例患者中，36（61%）为女性，其中23人（63.9%）为WOCBP。23例（39.0％）患者接受CZP作为其首次生物治疗。选择CZP的主要原因是其在PsO和PsA中的疗效，和WOCBP由于很少或没有跨胎盘转移。治疗3个月后观察到症状的改善，并维持12个月的分析期。经过12个月的治疗，患者平均PASI评分从基线时的13.0(±5.8)降至2.3(±4.3),平均BSA评分从13.1%(±6.7%)到1.7%(±2.6%)，平均PGA评分从3.0(±0.6)到0.8(±0.6)。CZP药物12个月生存率为76.3%,未接受生物学治疗的患者和有生物学经验的患者之间没有差异。
结论：CZP是有效的，并且在实际情况下，CZP在中重度PsO患者队列中具有良好的耐受性。
